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Background: Anthracycline adjuvant therapy has taken a particular role in the treatment of early stage breast
cancer with an associated decrease in rates of both relapse and death. Their success however has been limited by
their myelosuppression and their well-established risk of cardiac dysfunction. Guidelines have emerged that would
limit the maximum lifetime dose of anthracyclines and make a baseline assessment and periodic monitoring of
cardiac function part of the routine practice, which could be cumbersome, and may condemn the patient to an
unwarranted modification of his/her regimen. Our study aimed at assessing the incidence of abnormal baseline
echocardiography in asymptomatic women with breast cancer prior to anthracycline therapy and establishing risk
criteria associated with abnormal echocardiograms at baseline.
Methods: 220 Patients seen at AUBMC (American University of Beirut Medical Center) who had non- metastatic breast
cancer, and had an echocardiography performed before starting anthracycline chemotherapy were chosen. Data about
demographic characteristics, tumor characteristics, baseline echocardiography results, and change in clinical decision
was collected. Patients with suboptimal (less than 50%) ejection fraction (EF) on baseline echocardiography were
analyzed for the prevalence of cardiac risk factors. Results were compared to those among the overall study group
using Fisher’s Exact test. A p- value of = < 0.05 was used as reference for statistical significance.
Results: All 220 of our patients had received a baseline echo prior to initiation of anthracycline therapy. 6.7% of
these patients had already some abnormality in wall motion but only 2.7% had a suboptimal ejection fraction. 1.3%
had a change in chemotherapy regimen based on ejection fraction. The patients with depressed EF had higher rates
of CAD (coronary artery disease), diabetes, hypertension and dyslipidemia than the overall study group but without
statistical significance.
Conclusions: Our study, as well as the previous contingent studies raise the question about routine echocardiography
prior to anthracycline therapy and might eventually lead to a modification of current practice guidelines.
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Over the last few decades, the arsenal of chemotherapeutic
agents available to oncologists, and specifically breast can-
cer specialists has been constantly expanding. The use of
anthracyclines has become particularly universal and cen-
tral to every accepted treatment algorithm. Anthracycline
adjuvant therapy has taken a particular role in the* Correspondence: at35@aub.edu.lb
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unless otherwise stated.treatment of early stage breast cancer with an associated
decrease in rates of both relapse and death [1,2].
Commonly used anthracyclines in adjuvant regimens
however, such as Adriamycin and Epirubicin, are well
known for their cardiotoxicity that increases with factors
such as dosage, older age, use of other cardiotoxic agents
(such as trastuzumab), emphysema, diabetes and an
underlying cardiac disease [2-4]. Given their indispens-
able role, an intervention aimed at controlling their ill-
effects was a must. For instance, guidelines have
emerged that would limit the maximum lifetime dose ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[5,6]. Furthermore, a baseline assessment and periodic
monitoring of cardiac function (left ventricular ejection
fraction and wall motion abnormality) have been the
routine practice with any patient receiving cardiotoxic
chemotherapeutic agent regimens as per the recommen-
dation of the American College of Cardiology/American
Heart Association.
These precautionary practices, although at the time
justified with the prevailing data, are quite costly and
cumbersome, not only entailing additional visits, proce-
dures, and costs but also condemning the patient to an
unwarranted modification of his/her regimen that may
or may not be in his/her best interest. Many studies have
shown that it is in very few instances that physicians
have had to alter the anthracycline dosage, or regimen
itself, based on echocardiographic evidence of a de-
creased left ventricular function [3,5]. Furthermore, the
wide majority of previously healthy patients have been
shown to have consistently normal cardiac function at
baseline and on echocardiography follow-ups, despite
completing the recommended anthracycline course
[3,5,7]. And so the need for baseline echocardiography
and periodic monitoring of left ventricular function in
previously healthy and asymptomatic patients receiving
anthracyclines becomes debatable, especially that a
clear-cut cost effectiveness has not been established, nor
do chemotherapeutic protocols reach the toxic cumula-
tive maximal dose [6].
Practice at our center entails that all patients receiving
anthracycline as part of their chemotherapy protocol
undergo baseline investigative echocardiography. Screen-
ing is not only costly and cumbersome as mentioned
earlier but is far from flawless. The sensitivity and speci-
ficity of Echocardiography for the detection of Left ven-
tricular function are 80% and 88% respectively with a
positive predictive value of 86% [8] and so false positives
or negatives though unlikely, are possible, further adding
to the hazard of an unwarranted change in chemo regi-
men or dosage. Our current study aims at assessing the
incidence of an abnormal echocardiography result per-
formed on asymptomatic women with breast cancer
prior to anthracycline therapy and establish risk criteria
associated with abnormal echocardiograms at baseline.
The results of our data analysis will depict a pattern of
echocardiography impact on the physician’s choice of
chemotherapy regimen as well as weigh the need for a
baseline echocardiography in our population of breast
cancer patients. Our results are bound to have implica-
tions on future management and practice.
Methods
Patients seen at our center that had a diagnosis of
breast cancer between 2004 and 2012,underwent anechocardiography before starting the first chemotherapy
session and meeting the inclusion ciriteria, were the sub-
jects of this analysis and were chosen consecutively.
Those with metastatic disease (Stage IV disease) were
excluded from the study. Exclusion criteria also included
patients who didn’t receive anthracyclines irrespective of
their cardiac status, as well as those with a primary
breast lymphoma or phyllodes tumor.
This study was approved by the ethics committee of
the American University of Beirut International Review
Board and a consent form was waived.
The study followed a cross-sectional design. Patients’
records were reviewed in detail. Data collection included
demographic characteristics of patients, tumor charac-
teristics (stage, grade, TNM classification, laterality, hist-
ology, hormonal status…), medical history (dyslipidemia
(defined as LDL > 130, Triglycerides >150 or HDL <40),
diabetes (defined as a fasting plasma glucose of > 126),
hypertension (defined as a blood pressure superior to140
mmHg systolic or 90 mmHg diastolic, coronary artery
disease (atherosclerotic cardiovascular disease diagnosed
by baseline electrocardiography (ECG), stress ECG, echo-
cardiography or coronary angiography), signs/symptoms
of cardiac disease (chest pain, cough, orthopnea etc.),
smoking, menopausal status…), baseline echocardiog-
raphy results, clinical decision (chemotherapy regimen,
change in chemotherapy based on echocardiography re-
sults, previous chemotherapy, previous hormonal ther-
apy, surgery…). The echocardiography was performed at
AUBMC, in the noninvasive cardiac lab. Different meas-
urement apparatuses were used over the years and left
ventricular ejection fraction was assessed based on 2D
measurements.
Data entry was performed by independent lay persons
that were unaware of the objectives of the study. Data
cleaning was carried out by the researchers. Data ana-
lysis was performed using SPSS IBM version 20.0 and
initially aimed at identifying patients with an abnormal
echocardiography results, suboptimal ejection fraction
and those with a change in chemotherapy regimen based
on echocardiography results. Patients who turned out to
have a suboptimal ejection fraction at baseline echo-
cardiography were analyzed for the prevalence of dys-
lipidemia, hypertension, CAD, diabetes, smoking, and
morbid obesity. Results were compared to those among
the overall study group using Fisher’s exact test. A p-
value of = < 0.05 was used as reference for statistical
significance. A multivariate analysis using logistic regres-
sion was performed after ensuring the adequacy of our
data using the Hosmer and Lemeshow test, to detect any
association between EF at baseline and cardiovascular risk
factors (Baseline Ejection Fraction was the dependent
variable). Adjusted odds ratios and their 95% confidence
intervals were reported.
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A total of 220 patients met the study criteria and their
records were reviewed in detail. Table 1 summarizes pa-
tient characteristics. Essentially 98.6% were females with
a mean age of 51.5 years. This relatively young mean age
reflects the Lebanese breast cancer population whoseTable 1 Demographics and tumor characteristics
Variables Groups N Percentages
Stage 1 47 21.4
2 102 46.4
3 57 25.9
Not available 14 6.3
Grade 1 29 13.2
2 80 36.4
3 98 44.5
Not available 13 5.9
Laterality Right side 110 50
Left side 109 49.5
Bilateral 1 0.5
T 1 74 33.6
2 97 44.1
3 37 16.8
Not available 12 5.5




Not available 5 2.3
M 0 220 100
aER Negative 60 27.3
Positive 158 71.8
Not available 2 0.9
bPR Negative 78 35.5
Positive 140 63.6
Not available 2 0.9
cHER-2 Negative 118 53.6
Equivocal 67 30.5
Overexpressed 52 23.6
Not available 3 1.36
Previous hormone therapy (PHT) No PHT 131 59.6
Has had PHT 43 19.5
Not available 46 20.9
Menopausal status Premenopausal 90 40.9
Postmenopausal 109 49.5
Not available 21 9.6
aER: Estrogen Receptor Status. bPR: Progesterone Receptor Status.
cHER2: HER-2 Receptor Status.mean age at presentation has been reported at 50 [9].
Forty nine percent of patients were post-menopausal.
Around 68% of patients had stage I or II, and 45% had a
grade 3 tumor. Majority of tumors were ER/PR positive
(71.8% ER positive and 63.6% PR positive) and 23.6%
were her-2 overexpressing.
As per the inclusion criteria, all 220 of our patients re-
ceived a baseline echocardiogram prior to initiation of
anthracycline therapy. Fifteen (6.8%) of these patients
had some abnormality in wall motion but only 6 (2.7%)
had a suboptimal ejection fraction (less than 50%) and 3
of those, i.e. 1.35% had a change in chemotherapy regi-
men based on ejection fraction reading.
We reviewed the records of all of our patient popula-
tion for prevalence of cardiac disease risk factors
(Table 2). In Table 3, we compared the distribution of
cardiac risk factors among patients with abnormal echo
to those with normal echo, to see if it were these risk
factors that would explain the abnormal LVEF. Two of
the newly isolated group had a prior diagnosis of coron-
ary artery disease, two patients had diabetes, none of the
patients was a smoker, one patient was morbidly obese,
and two patients had dyslipidemia as compared to 2.3%
of the overall study group with coronary artery disease,
16% with diabetes, 24.3% with hypertension, 34.6%
smokers and 31.8% obese (BMI > 30) and so these risk
factors were more prevalent in the 6 patients that dem-
onstrated a clinically significant abnormal baseline echo-
cardiography as compared to the patients with normal
echocardiography. However, these differences were not
statistically significant (Table 3). A multivariate logistic
regression was performed as shown in Tables 4 and 5,Table 2 Study group risk factors for cardiac disease
Variables Groups N Percentages
Dyslipidemia No 170 77.2
Yes 40 18.2
Not available 10 4.6
Hypertension No 155 70.5
Yes 55 25
Not available 10 4.5
aCAD No 203 92.3
Yes 7 3.2
Not available 10 4.5
Diabetes No 175 79.5
Yes 36 16.4
Not available 9 4.1
Smoking No 131 59.5
Yes 74 33.6
Not available 15 6.9
aCAD: Coronary artery disease.
Table 3 Distribution of cardiac risk factors among
patients with abnormal echo compared to those with
normal echo - Fisher’s Exact test
Variable Normal echo Abnormal echo P value
Diabetes 0.3
No 171 (79.9) 4 (66.7)
Yes 34 (15.9) 2 (33.3)
Not available 9 (4.2)
Dyslipidemia 0.3
No 166 (77.7) 4 (66.7)
Yes 38 (17.6) 2 (33.3)
Not available 10 (4.7)
Hypertension 0.2
No 152 (71) 3 (50)
Yes 52 (24.3) 3 (50)
Not available 10 (4.7)
aCAD 0.01
No 199 (93) 4 (66.7)
Yes 5 (2.3) 2 (33.3)
Not available 10 (4.7)
Smoking status 0.1
No 126 (58.9) 5 (83.3)
Yes 74 (34.6) 0 (0)
Not available 14 (6.5) 1(16.7)
bBMI 1
<25 55 (25.7) 2 (33.3)
25-30 74 (34.6) 2 (33.3)
>30 68 (31.8) 1 (16.7)
Not available 17 (7.9) 1 (16.7)
aCAD: Coronary artery disease bBMI: Body Mass Index.
Table 4 Association between suboptimal EF at baseline
and risk factors
Variable Non Yes P value
Diabetes 0.3
Non 167 (83.1) 4 (66.7)
Yes 34 (16.9) 2 (33.3)
Dyslipidemia 0.3
No 163 (81.5) 4 (66.7)
Yes 37 (18.5) 2 (33.3)
Hypertension 0.2
No 149 (74.1) 3 (50.0)
Yes 52 (25.9) 3 (50.0)
aCAD 0.01*
No 195 (97.5) 4 (66.7)
Yes 5 (2.5) 2 (33.3)
Smoking status 0.1
No 124 (63.3) 5 (100.0)
Yes 72 (36.7) 0 (0.0)
bBMI
0 (18–25) 54 (28.0) 2 (40) 1.0
1 (25–30) 72 (37.3) 2 (40)
2 (30–35) 46 (23.8) 1 (20)
3 (35–40) 15 (7.8) 0 (0.0)
4 (>40) 5 (2.6) 0 (0.0)
5 (<18) 1 (0.5) 0 (0.0)
*P value < 0.05 statistically significant. aCAD: Coronary artery disease.
bBMI: Body Mass Index.
Table 5 Adjusted odds ratio with 95% confidence interval
for the logistic regression
Variable bOR 95 cCI P value
aCAD 4.2 2.1 – 15.4 0.01*
aCAD: Coronary artery disease, bOR: adjusted odds ratio, cCI: confidence
interval, *P value <0.05 statistically significant.
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95% CI (2.1-15.4) was the only risk factor that showed
significant association with a suboptimal baseline ejec-
tion fraction.
Discussion
Anthracycline cardiotoxicity has been well established in
the medical literature and its mechanisms well eluci-
dated. With their growing role in the management of
neoplastic diseases, particularly that of breast cancer,
precautionary measures such as baseline investigative
echocardiography has been the standard protocol in all
breast cancer patients being treated with an anthracy-
cline. Furthermore, a thorough and global assessment of
the clinical condition of the patient has become a must
as the cardiotoxicity rate associated with the commonly
used regimens (such as Adriamycin and Epirubicin) was
found to increase not only in a dose-dependent fashion
(cumulative dose and dose per treatment) but also withvarious unrelated factors such as other cardiotoxic drugs
(e.g. Trastuzumab), diabetes mellitus, the rate of ad-
ministration of the drug, a preexisting heart disease
(whether ischemic in nature or a decrease in the baseline
ejection fraction), previous mediastinal irradiation, age,
sex (female) etc. [10].
A look into our sample for the prevalence of such fac-
tors, particularly those that are predictors of cardiac dis-
ease, revealed that among the six patients who had
abnormal baseline echocardiography, two had coronary
artery disease (33.3%), 2 had dyslipidemia (33.3%), 2 had
diabetes (33.3%), None were smokers (0%), 1 was mor-
bidly obese (16.7%) and 3 were hypertensive (50%). The
prevalence of these comorbid conditions in these pa-
tients is more than that of patients with normal echo-
cardiography, however with no statistical significance.
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normal baseline EF, the association between risk factors
of cardiac disease and the presence of an abnormal
echocardiography at baseline cannot be established nor
denied. A multivariate logistic regression (Table 4) only
showed a statistically significant association between
baseline EF and Coronary Artery Disease. Perhaps a
larger sample would have decreed more solid and reli-
able associations. An additional limitation could have
been that our sample was extracted from a single med-
ical center, and our protocols, practices and patient
population does not necessarily reflect those of all other
reputable medical centers.
Conclusions
Out of 220 of our patients, only 6 had abnormal baseline
echocardiograms (2.7%), of which only 3 (1.35%) had a
change in chemotherapy regimen based on EF reading.
Hence, the impact of the baseline echocardiography on
the managerial decision of our oncologists has been mi-
nute. Also the association of irreversible cardiac myocyte
damage and long term sequelae with continuation of
treatment (within acceptable maximal doses) has not
been well exposed. Add to that the fact that screening
with echocardiography is far from flawless with a sensi-
tivity and specificity of 80% and 88% respectively [8],
giving room for false positives and negatives, as well as
the hazard of an unnecessary change in chemotherapy
regimen or dosage. All this is added to the psychological
and economic burdens such information might carry
over the patient’s well-being. With that in mind, our
study as well as previous contingent studies, raises the
question about routine echocardiography prior to
anthracycline therapy and might eventually lead to a
modification of current practice guidelines. Furthermore,
particular attention should be made to measures known
to limit anthracycline-associated cardiotoxicity such as
limiting the cumulative dose of doxorubicin to a range
of 450 mg/m2 to 550 mg/m2 [5,6], infusing the regimen
slowly, coadministration of a protective agent (dexrazox-
ane) when reaching high doses of anthracyclines and po-
tentially using the less cardiotoxic liposomal preparations
[10]. The benefit of the physician’s attentiveness and
awareness of these clinical elements and precautions,
could outweigh that of the baseline echocardiography
and avoid its cumbersome and hazardous implications
on both the patients’ management and well-being.
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